Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.

Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

J Immunol. 2007 Aug 1;179(3):1669-80.

2.

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.

Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS.

Blood. 2010 May 27;115(21):4293-301. doi: 10.1182/blood-2009-05-222190. Epub 2010 Mar 16.

4.

IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.

Sun K, Hsiao HH, Li M, Ames E, Bouchlaka M, Welniak LA, Hagino T, Jagdeo J, Pai CC, Chen M, Blazar BR, Abedi M, Murphy WJ.

J Immunol. 2012 Aug 15;189(4):2033-42. doi: 10.4049/jimmunol.1102853. Epub 2012 Jul 9.

5.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

6.

IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR, Ferrara JL.

J Clin Invest. 1999 Aug;104(3):317-25.

7.

Granzyme B-mediated damage of CD8+ T cells impairs graft-versus-tumor effect.

Bian G, Ding X, Leigh ND, Tang Y, Capitano ML, Qiu J, McCarthy PL, Liu H, Cao X.

J Immunol. 2013 Feb 1;190(3):1341-50. doi: 10.4049/jimmunol.1201554. Epub 2012 Dec 21.

9.

In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease.

Hartmann N, Leithäuser F, Albers C, Duyster J, Möller P, Debatin KM, Strauss G.

Leukemia. 2011 May;25(5):848-55. doi: 10.1038/leu.2011.16. Epub 2011 Feb 18.

PMID:
21331071
10.

Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts.

Delisle JS, Gaboury L, Bélanger MP, Tassé E, Yagita H, Perreault C.

Blood. 2008 Sep 1;112(5):2111-9. doi: 10.1182/blood-2007-12-130534. Epub 2008 Jun 13.

11.

Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.

Ito M, Shizuru JA.

Biol Blood Marrow Transplant. 1999;5(6):357-68.

12.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

14.

Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.

Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W, Taylor PA.

J Immunol. 2000 Nov 1;165(9):4901-9.

15.

Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease.

Maeda Y, Levy RB, Reddy P, Liu C, Clouthier SG, Teshima T, Ferrara JL.

Blood. 2005 Mar 1;105(5):2023-7. Epub 2004 Oct 5.

16.

Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JL, Burakoff SJ, van den Brink MR.

Blood. 2001 May 1;97(9):2886-95.

19.

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA.

Biol Blood Marrow Transplant. 2001;7(10):532-42.

20.

Supplemental Content

Support Center